Volume | 447,234 |
|
|||||
News | - | ||||||
Day High | 0.6015 | Low High |
|||||
Day Low | 0.5756 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Jaguar Health Inc | JAGX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.59 | 0.5756 | 0.6015 | 0.5945 | 0.57 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,476 | 447,234 | $ 0.5915985 | $ 264,583 | - | 0.4601 - 28.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:42:26 | 3 | $ 0.59 | USD |
Jaguar Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 11.43M | 19.11M | 19.10M | $ 1.97M | $ -124.04k | -2.39 | -92.11 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 317.00 | 1.40% |
Jaguar Health News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JAGX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.6477 | 0.688 | 0.564 | 0.6193752 | 656,492 | -0.0497 | -7.67% |
1 Month | 0.5564 | 1.22 | 0.5215 | 0.8833048 | 6,425,325 | 0.0416 | 7.48% |
3 Months | 1.25 | 1.39 | 0.4601 | 0.8546158 | 3,715,657 | -0.652 | -52.16% |
6 Months | 9.75 | 9.75 | 0.4601 | 5.09 | 5,143,747 | -9.15 | -93.87% |
1 Year | 26.3325 | 28.50 | 0.4601 | 10.23 | 4,380,527 | -25.73 | -97.73% |
3 Years | 33.00 | 335.22 | 0.4601 | 99.53 | 9,796,447 | -32.40 | -98.19% |
5 Years | 9,975.00 | 13,125.00 | 0.4601 | 293.70 | 6,649,468 | -9,974.40 | -99.99% |
Jaguar Health Description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. |